FAQ

Wnt-5a Mimic Hexapeptide Foxy-5

Known as: Foxy-5 
A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
0120082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Targeting the Dvl-1/β-arrestin2/JNK3 interaction disrupts Wnt5a-JNK3 signaling and protects hippocampal CA1 neurons during cerebral ischemia reperfusion.
It is well known that Wnt5a activation plays a pivotal role in brain injury and β-arrestin2 induces c-Jun N-terminal kinase (JNK3… (More)
Is this relevant?
2017
2017
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
Prostate cancer patients with high WNT5A expression in their tumors have been shown to have more favorable prognosis than those… (More)
Is this relevant?
2016
2016
Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
The tumor suppressor 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is the key enzyme in prostaglandin E2 catabolism and is down… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
Review
2012
Review
2012
Wnt-5a is a synaptogenic factor with neuroprotective properties against Aβ toxicity.
BACKGROUND We have recently found that Wnt-5a regulates the synaptic structure and function in hippocampal neurons. This ligand… (More)
  • figure 1
Is this relevant?
Review
2011
Review
2011
Retracted manuscript: The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer.
Retraction for: "The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERa negative breast… (More)
Is this relevant?
2009
2009
Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
One third of all breast cancers are estrogen receptor alpha (ERalpha) negative, carry a poor overall prognosis, and do not… (More)
Is this relevant?
Review
2009
Review
2009
The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer.
Despite improvements in detection and treatment, breast cancer remains the most common female cancer worldwide, and metastatic… (More)
Is this relevant?
2008
2008
The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility.
PURPOSE An inherent problem in breast cancer treatment is that current therapeutic approaches fail to specifically target the… (More)
Is this relevant?